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Surgical Treatment of the Endocrine Pancreas and Zollinger-Ellison
Syndrome in the MEN 1 Syndrome

isjorman W. Thompson'
Islet cell neoplasia is a frequent occurrence'inmultiple endocrine neoplasia type 1 {MEN 1). Sixteen
of 27 patients with MEN I developed functioning endocrine pancreatic tumor syndromes. Eleven of
the 16 developed Zollinger-Ellison syndrome and each was evaluated by a combination of computed
tomography and hepatic angiography to exclude hepatic metastasis and percutaneous transhepatic
catheterization to localize the tumor. Seven of the II patients were found to have duodenal
gastrinomas with multiple duodenal tumors in three patients. Four of the 11 patients had only
pancreatic gastrinomas. In addition to the gastrinomas, other types of islet tumors in the pancreatic
body or tail were found in nine ofthe 11 patients. None ofthe patients had hepatic metastases. Seven
of the 11 patients were trealed by distal pancrealectomy and since 1986 all patients have had
duodenotomies as part of the surgical e.xploialion. Postsurgical evaluation ranging from ihree
months to 14 years indicates lhal 10 of 11 patients have normal basal gastrin levels. We conclude that
duodenal gastrinomas are common in MEN I and can he managed successfully by appropriate
operative intervention. (Henry Ford Hosp Med J 1992:40:195-8)

ultiple endocrine neoplasia type 1 (MEN 1) is characterized by hyperplasia and neoplasms of the pituitary,
parathyroids, and pancreatic islets. Hyperparathyroidism (HPT)
occurs in more than 90% of patients and endocrine pancreatic
tumors in 60% (neariy all of whom have HPT as well). Approximately 40% of patients develop pituitary adenomas, most of
which secrete prolactin (1). In addition to the three principle organs involved, some of these patients develop adrenal cortical
tumors, bronchial carcinoids, and thymic carcinoids (2). The latter are usually malignant whereas the adrenal cortical tumors are
usually benign. In some families, subcutaneous lipomas are frequent and may require surgical treatment.
Our approach to the diagnosis of MEN 1 patients at the University of Michigan is to screen carefully for all components of
the syndrome in family members of those suspected of having
the syndrome after detection of a functioning islet-cell tumor
syndrome or primary HPT due to hyperplasia, particularly when
the individual glands are asymmetrically involved (1). During
the 15-year interval from 1976 to 1991, 27 patients with the
MEN 1 syndrome were identified. Of these, 16 were determined
to have functioning endocrine pancreatic tumor syndromes.
During the 15-year period, 11 patients in this group proven to
have the Zollinger-Ellison syndrome (ZES) were selected for
surgical treatment with the goal of excising their tumor(s) and
any lymphatic metastases present. The purpose of this paper is
to describe the surgical management of these patients and the results of their treatment.

M

Methods
The 11 patients with ZES were all proven to have the MEN 1
syndrome on the basis of family history and/or previous or con-
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comitant HPT and/or pituitary adenomas. The mean age ofthese
patients was 39 years at the time of treatment. There were seven
females and four males. All 11 patients had HPT. Nine had
parathyroidectomies before surgical treatment oftheir ZES (2-9
years) and two underwent parathyroidectomy at the same time
as their abdominal procedures. Seven of the 11 patients had pituitary adenomas, all of which secreted prolactin. Two patients
with Cushing's syndrome had unilateral functioning adrenal
cortical adenomas. All 11 patients had intact stomachs at the
time of surgical treatment.
Since 1978, after ruling out hepatic metastases (computed tomography and selective angiography), patients with MEN 1
ZES were selected for operation by percutaneous transhepatic
selective venous sampling (TVS) for gastrin. Regional localization of an elevated gastrin level was noted in each patient selected for operation (3,4).
Islet cell tumors in the head or uncinate process were enucleated after exploration of the entire pancreas and palpation of
the duodenum. Seven of the 11 underwent distal pancreatectomies regardless of the findings in the head or duodenum. Four
patients had tumors excised from the duodenum and/or pancreas
without a distal pancreatectomy. Since 1986, all patients had duodenotomies as part of their exploration. Patients with duodenal
tumors had regional dissections of periduodenal and peripancreatic lymph nodes.
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Table 1
Location of Gastrinomas in MEN 1 ZES Patients
Gastrinoma Location

Number of Patients
7/11
4/11
7/11
4/11
3/11

Pancreas
Pancreas only
Duodenum
Duodenum only
Duodenum and pancreas
Multiple gastrinomas
in duodenum
Other gross neuroendocrine
tumors in pancreas*

(64%)
(36%)
(64%)
(36%)
(27%)

3/11 (27%.)
11/11 (100%)

*Found in 9 of 11 at initial exploration.

Results
Gastrinomas were found in the pancreas in seven of 11 patients (64%). In three of these patients, additional gastrinomas
were found in the duodenum. Altogether, seven of 11 patients
had duodenal gastrinomas (64%). In three of the seven with duodenal gastrinomas, the tumors were multiple. Only 36% of patients had gastrinomas only in the pancreas. However, grossly
apparent tumor(s) were found in the pancreatic body or tail in
nine of 11 (82%). Most ofthese tumors stained negative for gastrin. All gastrinomas were verified by positive immunohistological study (Table 1).
None of the patients had liver metastases. Six (55%) patients
had meta.static lymph nodes. Five of seven (71 %) with duodenal
gastrinomas were proven to have metastatic lymph node involvement. One patient with a small concomitant neuroectodermal (NE) tumor of the body (somatostatinoma) had one node
staining positive only for somatostatin. This was the only patient who had a concomitant malignant pancreatic NE tumor
(Table 2).
In the pancreas of seven patients who had initial distal pancreatectomies, one or more NE tumors were found in each. None
of these patients has developed a recurrent NE tumor. A distal
pancreatectomy was not performed in four patients, three of
whom developed recurrent hormonal syndromes. Two patients
required a distal pancreatectomy for a gastrinoma in the body.
Early in this experience, two patients had concomitant total gastrectomies and two had vagotomies and pyloroplasties. The remaining seven patients have intact stomachs with vagal innervation. Thus, nine of the 11 patients still have intact stomachs.
After periods ranging from three months to 14 years, 10 of 11
(91 %) patients have normal basal gastrin levels. Currently, three
Table 2
Malignant Gastrinomas in MEN 1 ZES Patients
Type
Malignant duodenal gastrinomas
Malignant pancreatic gastrinomas
Malignant NE tumor of pancreas
Metastatic lymph nodes
Liver metastases
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Number of Patients
511 (71%)
0/4 (0%)
1/11 (9%)
6/11 (.55%)
0/11 (0%)

of 11 have negative secretin stimulation tests and can be categorized as biochemical as well as clinical "cures." One patient,
who underwent a distal pancreatectomy for an 8 cm gastrinoma
in 1977, died in 1991 from chronic heart disease. Her basal semm gastrin levels and secretin stimulated gastrin levels remained normal throughout her follow-up period.
Although the other seven patients with normal basal gastrin
levels have positive secretin tests, they are clinically free of
symptoms and have required no dmg therapy for periods ranging from three months to 13 years. Two patients required reoperation for hyperinsulinoma but had no evidence of recurrent gastrinoma. One patient, who required a reoperation for a second
gastrinoma seven years after resection of a primary gastrinoma
in the pancreatic body, currently has a negative secretin study
six months following the second operation. One patient with
three primary duodenal gastrinomas and one in the pancreatic
neck associated with large peripancreatic lymph node metastases has a persistently elevated basal gastrin level (300 to 500 pg/
mL) and requires omeprazole to remain free of symptoms.

Discussion
The most frequent clinical manifestation of MEN 1 pancreatic involvement is ZES, usually developing during the third or
fourth decade of life but often not diagnosed or treated until after
a number of symptomatic years despite the fact that most of
these patients have had HPT treated surgically at an earlier age
(1-6). Insulinomas are the second most common functional tumors in MEN 1 patients and may develop at any age. Although
30% of all ZES patients are found to have the MEN 1 syndrome,
the great majority of insulinomas are sporadic and only about
4% to 5% are determined to be MEN 1. Additional pancreatic
tumors found in MEN 1 patients are VIPomas, glucagonomas,
somatostatinomas, and polypeptidomas (PPomas) (1). In some
MEN 1 patients, tumors may develop and metastasize to lymph
nodes or the liver without any clinical manifestations whatsoever. Occasionally more than one functional hormone syndrome
may develop in the same MEN 1 patient. Most often this occurs
asynchronously as was the case in two of the patients in this series. Most patients with pancreatic disease requiring surgical intervention present with a single syndrome caused by hypersecretion of a specific hormone. However, in some patients, a tumor may be detected by an imaging study obtained only after
screening studies have shown an elevation of one or more
hormones such as pancreatic polypeptides or somatostatin.
The surgical treatment of MEN 1 pancreatic disease is controversial (7-12). One ofthe major issues centers around the fact
that virtually all patients with MEN 1 pancreatic disease have a
diffuse islet-cell hyperplasia expressed as nesidioblastosis, islet-cell hyperplasia, microadenomatosis, and/or benign or malignant islet-cell tumors (13). As a result, some have concluded
that a true cure of the pancreatic disease can only be achieved by
total pancreatectomy. Furthermore, the malignant potential of
MEN 1 islet-cell neoplasms has been considered relatively low.
Nevertheless, there is accumulating evidence that the majority
of gastrinomas in MEN 1 patients are in fact malignant and that
lymph node and/or hepatic metastases will develop in most pa-
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tients with ZES if followed for a long enough period (6). Other
functional and silent NE neoplasms in these patients also have
malignant potential. Patients with ZES pose a special problem
because the gastrinomas are often small, multiple, found in both
duodenum and pancreas, and associated with other NE tumors
(5). Because surgical attempts to control hypergastrinemia have
frequently failed in the past, many surgeons have recommended
only medical therapy until or unless a tumor has been imaged by
computed tomography or other studies (9-12,14-18). Even in
these cases, failure is likely because the imaged tumor excised is
often not a gastrinoma. It has been our contention that many of
these patients could be successfully treated surgically, providing all tumors secreting gastrin could be found and excised with
any metastatic lymph nodes involved (7,8). This opinion was
based on the fact that in previous immunohistological studies of
MEN 1 pancreases, we found that only discrete tumors stained
positive for gastrin and that the more diffusely involved islets
and pancreatic microadenomas were consistendy negative for
gastrin (13).
After ruling out hepatic metastases in MEN 1 ZES patients, it
has been our policy to perform TVS for gastrin and to explore
those patients demonstrating regionalized, rather than diffuse,
secretion of gastrin as determined by these studies (3,8). Most
patients were found to have gastrinomas in the head or duodenal
region although several have had primary gastrinomas in the
body or tail with or without other gastrinomas in the duodenum.
Because the duodenum is such a common site for gastrinomas in
MEN 1 patients, we began to perform a duodenotomy routinely
in all patients after 1986. The entire duodenal mucosa must be
carefully evaluated by eversion and gentle palpation because
these tumors may be as small as 1 mm and are often multiple in
MEN 1 patients (19,20). Furthermore, even these very small tumors may be malignant and have already metastasized to contiguous lymph nodes. As a result, routine periduodenal and peripancreatic lymph node dissection is essential whenever a duodenal gastrinoma is found, regardless of size. Five of seven
(71%) patients with duodenal tumors in this series had metastatic nodal involvement. Duodenal gastrinomas less than 0.5
cm are usually not invasive and can be locally excised, whereas
larger gastrinomas must be excised with a margin of full thickness duodenal wall. In a similar experience, Pipeleers-Marichal
and colleagues (5) emphasized the importance of duodenal gastrinomas in MEN 1 patients. They found that 100% of eight
MEN 1 patients had duodenal gastrinomas and in five cases
these were multiple. There were regional lymph node metastases found in four of eight (50%) (5). In addition to excision of
the duodenal disea.se, any palpable tumors in the head or uncinate process should be enucleated. We have encountered no
pancreatic gastrinomas that were locally invasive and could not
be excised with techniques similar to those used to remove benign insulinomas of the head. For the past decade we have, with
few exceptions, also performed a distal pancreatic resection
even when no palpable tumors have been identified. In the four
patients in which the body and tail were not resected, three developed recurrent disease; two multiple insulinomas and one a
new gastrinoma. The fourth patient had a single NE tumor excised from the tail of the pancreas at thetimeof exploration fol-
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lowing excision of three gastrinomas from the duodenum, two
from the pancreatic head, and several metastatic peripancreatic
lymph nodes. This patient remains eugastrinemic and has a negative secretin study three years after this operation. The other
three patients have subsequently undergone reoperation distal
pancreatectomies, achieving a "cure" of their syndromes. As a
result, all 11 MEN 1 patients have been found to have grossly
palpable tumors in their distal pancreas during the course of
their disease. Currently, our distal resection is from the superior
mesenteric vein, usually preserving the spleen by careful ligation of the small vessels from the splenic artery and vein.
The results in this series are contrary to those reports by others in which no patient's serum gastrin levels were normalized
(10-12,14,16,18). All but one of our patients currendy has a normal basal gastrin level and three have negative secretin tests.
One of the latter developed recurrence of hypergastrinemia
seven years after having tests. One of the latter developed recurrence of hypergastrinemia seven years after having normal basal
levels but consistently positive secretin studies. At a second operation, a gastrinoma was found at the junction of the pancreatic
neck and body. Three patients in the positive secretin group but
with normal basal gastrin levels developed elevations of serum
gastrin from one to six years after being eugastrinemic, concurrent with the development of recurrent HPT and hypercalcemia.
In each, the basal serum gastrin level retumed to normal after
successful reoperations for HPT. Only the one patient with persistent hypergastrinemia has required other than short-term drug
therapy for symptomatic hyperacidity during the time of this
study. Similar results were recently reported by Pipeleers-Marichal et al (5). In their series of six MEN 1 patients who underwent surgical exploration and excision of duodenal gastrinomas, four were eugastrinemic at the time of follow-up.
Our results with an aggressive surgical approach to the MEN
1 ZES patient suggest that all patients should be explored if the
liver is free of metasta.ses, with the intent of performing a distal
pancreatectomy, duodenal exploration, enucleation of any tumors in the head, and a peripancreatic lymph node dissection.
Thus far, all of our patients have had discrete gastrinomas rather
than diffuse hyperplasia or microadenomatosis as the source of
their gastrin hypersecretion. Furthermore, the incidence of malignancy has been found to be similar to that in patients with
sporadic ZES (60%), although fewer patients have had liver metastases. Although not yet proven with certainty, it appears that
the biologic behavior of malignant duodenal gastrinomas which
metastasize to lymph nodes is distinctly different from that of
tumors which initially metastasize to the liver. Despite the presence of lymph node metastases, if the primary tumor and all
nodes are excised, most of these patients may be cured of their
disease (21-23). Curative resection appears to be possible in the
former group whether they are sporadic or MEN 1 patients with
gastrinomas.
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